Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Fitstry vs Genesis Lifestyle Medicine

Fitstry
Graded #292

Higher grade

vs+3.799999999999997
Genesis Lifestyle Medicine
Graded #392

Lower grade

The verdict

Fitstry takes it — 61.5/100 to 57.7/100.

Fitstry grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Fitstry is the GLP-1 weight-loss program of Weightstry, LLC, a LegitScript-certified, cash-pay telehealth practice focused on women 40+.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGenesis Lifestyle Medicine +15
30
45
Dose & formulationFitstry +22
75
53
Clinical oversightFitstry +3
81
78
Labs & monitoringFitstry +21
73
52
FulfillmentEven
67
67
Contract termsGenesis Lifestyle Medicine +8
47
55
Fitstry · left barGenesis Lifestyle Medicine · right bar

The numbers

MetricFitstryGenesis Lifestyle Medicine
WeighScore61.5/10057.7/100
GradeCC
Scorecard rank#292#392
Semaglutide$179/mo (annual plan, plus a separate fee, compounded)Not disclosed
Tirzepatide$269/mo (annual plan, compounded)Not disclosed
CoverageCoverage not published8 states
Brand-name accessCompounded onlyYes
Oral / sublingualYesInjection only
Fitstry

Graded #292 · C

Strengths

  • Transparent pricing before you commit — compounded semaglutide from $179/mo, tirzepatide from $269/mo, oral GLP-1 from $209/mo (annual plan)
  • Free screening with a one-time $99 program fee that is fully refunded if a clinician can't prescribe ('Approved, or Your $99 Back')
  • Monthly price bundles a lab panel (CMP, A1c, lipids, TSH), unlimited clinician access, bi-weekly care coaching and a 24/7 Care Line
  • Runs under Weightstry, LLC, a LegitScript-certified practice with an independently verifiable seal, a named support email and phone
  • Full compounded lineup — weekly injection, daily oral tablet and microdosing options

Where it loses points

  • Month-to-month pricing is notably higher than the annual plan ($249 vs $179 semaglutide, $339 vs $269 tirzepatide)
  • Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
  • Framed for women 40+, and serves 49 states rather than all 50 (the excluded state isn't disclosed publicly)
  • Works with state-licensed compounding pharmacies but doesn't name a specific pharmacy partner on the Fitstry page
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name

Strengths

  • 18 physical clinics allow in-person consults and injections across 8 states
  • Dual modality — compounded sema/tirz plus brand-name Wegovy and Zepbound on one platform
  • Med spa model lets patients combine weight loss, hormone therapy, and aesthetics
  • Established brand with an 18-location footprint and patient testimonials
  • Telehealth available for remote patients in served states

Where it loses points

  • Pricing not disclosed publicly — gated behind the consultation flow
  • Specific 503A/503B pharmacy partner not named, and the designation not specified
  • No FDA compounded-medication disclaimer visible on the homepage
  • Named medical director not formally disclosed (only a 'Dr. Spinoso' testimonial)
  • Corporate legal entity and governing law not disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard